A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs Alectinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ALERT-lung
- 31 Aug 2018 Status changed from not yet recruiting to recruiting.
- 13 Aug 2018 Planned initiation date changed from 1 Jun 2018 to 1 Aug 2018.
- 15 May 2018 Planned End Date changed from 1 Mar 2023 to 1 Jun 2023.